RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.
Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.
- Interesting? Share this article
Other news
First liver cancer patient treated with microspheres irradiated in TU Delft
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
LinkedIn post ESRR2024
📢 Important update on EU #GMP Annex 1 at #ESRR2024! The revised EU GMP Annex 1, effecti...
Production of novel diagnostic radionuclides in small medical cyclotrons
Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...
LinkedIn post Isologic goes electric
🔌Isologic Goes Electric! We are excited to announce the expansion of our electric fleet with the a...
Interested in a collaboration?
Contact us to discuss the possibilities.